Riboxin - instructions for use. Pharmacological action and correct dosage of riboxin Method of application of riboxin in ampoules

Riboxin: instructions for use and reviews

Latin name: Riboxin

ATX Code: C01EB

Active substance: Inosine (Inosine)

Manufacturer: Binnopharm CJSC (Russia); Aspharma (Russia); Ozon OOO (Russia); Irbit Chemical Pharmaceutical Plant (Russia); Borisov Plant of Medical Preparations (Republic of Belarus)

Description and photo update: 13.08.2019

Riboxin is a drug that regulates metabolic processes, has an antihypoxic and antiarrhythmic effect.

Release form and composition

• Film-coated tablets: round, biconvex, yellow; tablet core - white or almost white (in a blister pack of 10 pcs., in a carton pack of 1-5 or 10 packs; in a blister pack of 25 pcs., in a carton pack of 1-5 or 10 packs; 50 pcs. in a polymer jar, in a carton pack 1 jar, 50 pieces in a dark-colored glass jar, in a carton pack 1 jar);
• Film-coated tablets: biconvex, from yellow-orange to light yellow, two layers are visible when cut (in a blister pack of 10 pieces, in a carton pack 1, 2, 3, 4 or 5 packs);
• Solution for intravenous (in / in) administration: a colorless or slightly colored transparent liquid (5 and 10 ml each in neutral-colored glass ampoules: 10 ampoules in a carton pack; 5 or 10 pcs. in a blister pack, in a carton pack 1 or 2 packs);
• Capsules: No. 1, gelatinous, hard structure, red, inside the capsules - white powder (in a blister pack of 10 pcs., in a carton pack of 5 packs).

1 film-coated tablet contains:

• Active ingredient: inosine (riboxin) - 0.2 g;
• Auxiliary components: lactose monohydrate, microcrystalline cellulose, copovidone, calcium stearate;
• Shell composition: Opadry II (series 85) (macrogol-3350, partially hydrolyzed polyvinyl alcohol, titanium dioxide (E171), aluminum lacquer based on sunset yellow dye (E110), aluminum lacquer based on indigo carmine (E132), aluminum lacquer based on dye quinoline yellow (E104), talc).

1 coated tablet contains:

• Auxiliary components: sugar, potato starch, titanium dioxide, water-soluble methylcellulose, tween-80, tropeolin O, stearic acid.

1 ml solution for intravenous administration contains:

• Active ingredient: inosine - 0.02 g;
• Auxiliary components: hexamethylenetetramine (methenamine), 1M sodium hydroxide solution, water for injection.

1 capsule contains:

• Active ingredient: inosine - 0.2 g;
• Auxiliary components: potato starch, calcium stearate;
• Shell composition: pharmaceutical gelatin, methyl parahydroxybenzoate, glycerol, propyl parahydroxybenzoate, titanium dioxide, Alluring Red dye (E129), sodium lauryl sulfate, purified water.

Pharmacological properties

Pharmacodynamics

Riboxin is a drug that regulates metabolic processes. It belongs to the category of purine derivatives (nucleosides) and is a precursor of adenosine triphosphate (ATP). Riboxin is characterized by antiarrhythmic, metabolic and antihypoxic effects. It normalizes the energy balance of the myocardium, stabilizes coronary circulation, eliminates the consequences of renal intraoperative ischemia.

This substance is directly involved in glucose metabolism and activates metabolism in the absence of ATP and under conditions of hypoxia. Riboxin accelerates the metabolism of pyruvic acid, which contributes to the normalization of the process of tissue respiration, and also ensures the activation of xanthine dehydrogenase. The drug stimulates the production of nucleotides and increases the activity of certain enzymes of the Krebs cycle. Riboxin penetrates into cells, improving energy metabolism and positively affecting metabolic processes in the myocardium: the compound increases the strength of heart contractions and provides more complete relaxation of the myocardium in diastole. As a result, the stroke volume of the blood increases. Riboxin inhibits platelet aggregation and improves tissue regeneration (mainly the gastrointestinal mucosa and myocardium).

Pharmacokinetics

Riboxin is well absorbed from the gastrointestinal tract and metabolized in the liver, forming glucuronic acid, which is further oxidized. The compound is excreted in small amounts through the kidneys.

Indications for use

According to the instructions, Riboxin is used as part of complex therapy:

• Period after myocardial infarction;
• Cardiac ischemia;
• Violation of the heart rhythm against the background of the use of cardiac glycosides;
• Myocardial dystrophy;
• Liver diseases: fatty degeneration, hepatitis, cirrhosis;
• Urocoproporphyria.

In addition, a solution for intravenous administration is prescribed during surgery on an isolated kidney for pharmacological protection when blood circulation is turned off.

Contraindications

• Age up to 18 years;
• Gout;
• Hyperuricemia;
• The period of pregnancy and breastfeeding;
• Individual intolerance to the components of the drug.

In addition, the use of film-coated tablets is contraindicated in patients with lactase deficiency, lactose intolerance, glucose-galactose malabsorption.

Instructions for use Riboxin: method and dosage

Film-coated tablets and film-coated tablets

Riboxin tablets are taken orally before meals.

Recommended dosing regimen: at the beginning of therapy - 0.2 g 3-4 times a day, after 2-3 days of treatment (with adequate tolerance of the drug), the patient is transferred to receive 0.4 g 3 times a day. To achieve a therapeutic effect, a gradual increase in the dose is possible, but not more than up to 2.4 g per day. The duration of the course is 30-90 days.

For the treatment of urocoproporphyria, 0.2 g is prescribed 4 times a day for 30-90 days.

Solution for intravenous administration

A solution of Riboxin is administered slowly in / in a stream or drip. The infusion rate should not exceed 40-60 drops per 1 minute.

To prepare the infusion solution, it is necessary to mix the drug solution with 250 ml of 0.9% sodium chloride solution or 5% glucose solution.

Recommended dosing for intravenous drip: initial dose - 0.2 g (10 ml) 1 time per day. With a good response to the drug, the dose can be increased to 0.4 g (20 ml) 1-2 times a day. The course of treatment is 10-15 days.

Dosing regimen for jet administration:

• Acute cardiac arrhythmias: a single dose of 0.2-0.4 g (10-20 ml of solution);
• Pharmacological protection of the kidneys: a single injection 5-15 minutes before turning off the blood circulation - 1.2 g (60 ml), then immediately after the restoration of the hepatic artery - 0.8 g (40 ml).

Capsules

The capsules are intended to be taken orally before meals.

Recommended dosage: initial dose - 1 pc. 3-4 times a day, with adequate tolerability of the drug for 2-3 days of therapy, to achieve the desired effect, the dose can be increased to 2 pcs. 3 times a day (1.2 g). The daily dose should not exceed 12 pcs. (2.4 g).

With urocoproporphyria, the patient is prescribed 1 pc. 4 times a day.

The duration of treatment is 30-90 days.

Side effects

• Allergic reactions: possibly - skin hyperemia, skin itching;
• Others: rarely - an increase in the level of uric acid in the blood, against the background of long-term therapy - exacerbation of gout.

In addition, the use of Riboxin capsules and tablets can cause an allergic reaction in the form of urticaria.

Overdose

With the introduction of Riboxin in high doses, the patient may experience an increase in individual sensitivity reactions to the drug. In this case, the drug is canceled and desensitizing therapy is prescribed. Sometimes there is an increase in the concentration of uric acid in the blood, causing an exacerbation of the condition in patients with gout and requiring the abolition of Riboxin.

special instructions

It is not recommended to prescribe Riboxin for emergency assistance in case of violation of the activity of the heart.

With the appearance of skin hyperemia, immediate withdrawal of the drug is required.

The use of the drug should be accompanied by regular monitoring of the level of concentration of uric acid in the urine and blood.

Does not affect the patient's ability to drive vehicles and mechanisms.

drug interaction

The action of inosine as part of complex therapy increases the effectiveness of antianginal, antiarrhythmic, inotropic drugs.

The concomitant use of immunosuppressants (including antithymocyte immunoglobulin, gamma-D-glutamyl-D-tryptophan, cyclosporine) reduces the effectiveness of inosine.

No other clinically significant interactions of Riboxin have been established.

Analogues

The analogues of Riboxin are: Inosie-F, Inosin, Inosin-Eskom, Riboxin Bufus, Riboxin-Vial, Riboxin-LekT, Riboxin-Ferein, Ribonosin.

Terms and conditions of storage

Keep out of the reach of children and protected from light at temperatures up to 25 ° C, protect tablets and capsules from moisture.

Shelf life: tablets and solution - 3 years, capsules - 2 years.

In this article, you can read the instructions for using the drug Riboxin. Reviews of site visitors - consumers of this medicine, as well as opinions of doctors of specialists on the use of Riboxin in their practice are presented. A big request to actively add your reviews about the drug: did the medicine help or not help get rid of the disease, what complications and side effects were observed, perhaps not declared by the manufacturer in the annotation. Analogues of Riboxin in the presence of existing structural analogues. Use for the treatment of myocardial infarction, hepatitis and other metabolic diseases in adults, children, as well as during pregnancy and lactation.

Riboxin- refers to a group of drugs that regulate metabolic processes. The drug is a precursor for the synthesis of purine nucleotides: adenosine triphosphate and guanosine triphosphate. The active substance of the drug is Inosine.

It has antihypoxic, metabolic and antiarrhythmic effects. Increases the energy balance of the myocardium, improves coronary circulation, prevents the consequences of intraoperative renal ischemia. It is directly involved in the metabolism of glucose and contributes to the activation of metabolism in conditions of hypoxia and in the absence of adenosine triphosphate.

It activates the metabolism of pyruvic acid to ensure the normal process of tissue respiration, and also contributes to the activation of xanthine dehydrogenase. Stimulates the synthesis of nucleotides, enhances the activity of some enzymes of the Krebs cycle. Penetrating into the cells, it increases the energy level, has a positive effect on metabolic processes in the myocardium, increases the strength of heart contractions and contributes to a more complete relaxation of the myocardium in diastole, resulting in an increase in stroke volume.

Reduces platelet aggregation, activates tissue regeneration (especially myocardium and mucous membrane of the gastrointestinal tract.

Pharmacokinetics

Well absorbed in the gastrointestinal tract. It is metabolized in the liver with the formation of glucuronic acid and its subsequent oxidation. In a small amount excreted by the kidneys.

Indications

• myocardial dystrophy;
• condition after myocardial infarction;
• congenital and acquired heart defects;
• cardiac arrhythmias, especially with glycoside intoxication;
• myocarditis;
• dystrophic changes in the myocardium after heavy physical exertion and past infectious diseases or due to endocrine disorders;
• hepatitis;
• cirrhosis of the liver;
• fatty degeneration of the liver, incl. caused by alcohol or drugs;
• prevention of leukopenia during radiation exposure;
• operations on an isolated kidney (as a means of pharmacological protection in case of a temporary lack of blood circulation in the operated organ).

Release forms

Film-coated tablets 200 mg.

Capsules 200 mg.

Solution for intravenous administration (injections in ampoules for injection) 20 mg / ml.

Instructions for use and dosing regimen

Tablets, capsules

Assign adults inside, before meals.

The daily dose for oral administration is 0.6-2.4 g. In the first days of treatment, the daily dose is 0.6-0.8 g (200 mg 3-4 times a day). In case of good tolerance, the dose is increased (for 2-3 days) to 1.2 g (0.4 g 3 times a day), if necessary, up to 2.4 g per day.

Course duration - from 4 weeks to 1.5-3 months.

With urocoproporphyria, the daily dose is 0.8 g (200 mg 4 times a day). The drug is taken daily for 1-3 months.

Ampoules

When taken orally, the initial daily dose is 600-800 mg, then the dose is gradually increased to 2.4 g per day in 3-4 doses.

With intravenous (stream or drip in the form of a dropper) administration, the initial dose is 200 mg 1 time per day, then the dose is increased to 400 mg 1-2 times a day.

The duration of the course of treatment is set individually.

Side effect

• allergic reactions in the form of urticaria, pruritus, skin hyperemia (drug withdrawal is required);
• increase in the concentration of uric acid in the blood and exacerbation of gout (with prolonged use).

Contraindications

• hypersensitivity to the drug;
• gout;
• hyperuricemia;
• children's age up to 3 years;
• fructose intolerance and glucose/galactose malabsorption syndrome or sucrase/isomaltase deficiency.

Use during pregnancy and lactation

The safety of Riboxin during pregnancy and lactation has not been established. The use of the drug Riboxin is contraindicated during pregnancy. At the time of treatment with Riboxin, breastfeeding should be stopped.

Use in children

Contraindicated in children under the age of 3 years.

special instructions

During the period of treatment with Riboxin, the concentration of uric acid in the blood and urine should be monitored.

Information for patients with diabetes mellitus: 1 tablet of the drug corresponds to 0.00641 bread units.

Does not affect the ability to drive vehicles and control mechanisms that require increased concentration.

drug interaction

Immunosuppressants (azathioprine, antilympholin, cyclosporine, thymodepressin, etc.) with simultaneous use reduce the effectiveness of Riboxin.

Analogues of the drug Riboxin

Structural analogues for the active substance:

• Inosie-F;
• Inosine;
• Inosin-Eskom;
• Riboxin Bufus;
• Riboxin-Vial;
• Riboxin-LekT;
• Riboxin-Ferein;
• Riboxin solution for injections 2%;
• Ribonosin.

In the absence of analogues of the drug for the active substance, you can follow the links below to the diseases that the corresponding drug helps with and see the available analogues for the therapeutic effect.

1 ml of solution contains

active substance: inosine - 20 mg;

excipients: hexamethylenetetramine, 1 M sodium hydroxide solution, water for injection.

Description

Clear colorless liquid

Pharmacotherapeutic group

Other cardiotonic drugs.

ATC code C01EV

Pharmacological properties

Pharmacokinetics

When administered intravenously, riboxin is rapidly distributed in tissues, metabolized in the liver, where it is completely utilized in the biochemical reactions of the body. Excreted mainly with urine.

Pharmacodynamics

Riboxin is a metabolic drug that has antihypoxic and antiarrhythmic effects. It is a precursor of ATP, is directly involved in glucose metabolism and contributes to the activation of metabolism under conditions of hypoxia and in the absence of ATP. The drug activates the metabolism of pyruvic acid to ensure the normal process of tissue respiration and promotes the activation of xanthine dehydrogenase.

Riboxin has a positive effect on the metabolism in the myocardium, in particular, it increases the energy balance of cells, stimulates the synthesis of nucleotides, and increases the activity of a number of enzymes of the Krebs cycle. The drug normalizes the contractile activity of the myocardium and contributes to the complete relaxation of the myocardium in diastole due to the ability to bind calcium ions that have penetrated the cells during their excitation, activates tissue regeneration (especially the myocardium and the mucous membrane of the digestive canal).

Application in pediatrics

Children under 12 years of age are prescribed depending on weight, at the rate of 10-20 mg / kg of body weight (divided into 2-3 doses).

The duration of the course of treatment is determined by the attending physician.

Indications for use

Ischemic heart disease, incl. myocardial infarction, angina pectoris, coronary insufficiency (as part of complex therapy)

Heart rhythm disorders

Intoxication with drugs of cardiac glycosides

Treatment of cardiomyopathies of various origins, myocardial dystrophies (due to heavy physical exertion, infectious and endocrine origins), myocarditis

Liver diseases (hepatitis, liver cirrhosis, fatty liver)

To improve visual functions in open-angle glaucoma with normalized intraocular pressure.

Dosage and administration

Adults and children over 12 years of age are prescribed intravenously by drip or jet. First, 200 mg (10 ml of a 2% solution) is administered 1 time per day, then, with good tolerance, up to 400 mg (20 ml of a 2% solution) 1-2 times a day. The course of treatment is determined individually (average 10-15 days). With drip injection into a vein, a 2% solution of the drug is diluted in 5% glucose solution or 0.9% sodium chloride solution (up to 250 ml). The drug is injected slowly, 40-60 drops per 1 minute. In case of acute cardiac arrhythmias, jet administration in a single dose of 200-400 mg (10-20 ml of a 2% solution) is possible.

Side effects

Arterial hypotension, tachycardia, general weakness

Hyperemia and itching of the skin

Allergic reactions (urticaria, angioedema, fever, shortness of breath)

Lipodystrophy

In rare cases, during treatment, an increase in the level of uric acid in the blood may occur, with prolonged treatment - exacerbation of gout.

Contraindications

Increased individual sensitivity to the drug

Gout

Hyperuricemia

Restriction to taking Riboxin is renal failure.

Drug Interactions

When used as part of complex therapy, Riboxin enhances the effectiveness of antiarrhythmic, antianginal and inotropic drugs.

With the simultaneous use of Riboxin with beta-blockers, the effect of Riboxin does not decrease. In combination with cardiac glycosides, the drug can prevent the occurrence of arrhythmias and enhance the inotropic effect.

With simultaneous use with immunosuppressants, the effectiveness decreases.

Clinically significant interaction of Riboxin with drugs from other groups has not been described.

Riboxin should not be mixed in the same syringe with other drugs in order to avoid chemical incompatibility of drugs.

special instructions

In renal insufficiency, the use of the drug is possible only when, in the opinion of the doctor, the expected positive effect outweighs the possible risk of use.

During treatment, you should regularly monitor the level of uric acid in the blood.

With caution, the drug is prescribed for violations of kidney function.

With the appearance of itching and hyperemia of the skin, the drug should be discontinued.

Application in pediatrics

In children over 12 years of age, it is prescribed taking into account the benefit / risk ratio.

Pregnancy and lactation

During pregnancy and lactation, Riboxin is prescribed taking into account the benefit / risk ratio.

Features of the influence of the drug on the ability to drive a vehicle or potentially dangerous mechanisms

Care should be taken when driving vehicles and potentially hazardous activities that require increased concentration.

Riboxin is a drug that regulates metabolic processes in the myocardium, reduces tissue hypoxia, and improves coronary circulation.

It has antihypoxic, metabolic and antiarrhythmic effects. Increases the energy balance of the myocardium, improves coronary circulation, prevents the consequences of intraoperative renal ischemia.

It is directly involved in the metabolism of glucose and contributes to the activation of metabolism in conditions of hypoxia and in the absence of adenosine triphosphate.

Clinical and pharmacological group

A drug that normalizes myocardial metabolism, reduces tissue hypoxia.

Terms of sale from pharmacies

Can be bought without a doctor's prescription.

Price

How much does Riboxin cost in pharmacies? The average price is at the level of 60 rubles.

Composition and form of release

Traditionally, the drug is produced in the form factor of tablets, which are covered with a special film coating. The color of the tablets varies from yellowish to yellow-orange. The tablets are biconvex, round, slightly rough, when cut, it is clear that the core has a white color.

• The main substance of the drug is inosine. Excipients are also available, including stearic acid, methylcellulose, potato starch and sucrose. The shell also contains yellow opadra II.

An alternative form of release is capsules with a 2% solution, which are used when injections of this drug are made.

pharmachologic effect

Inosine, which is the active ingredient of Riboxin, helps regulate metabolic processes. The drug has antihypoxic and antiarrhythmic action. It is able to accelerate metabolic processes in the myocardium and positively influence metabolic processes in the heart muscle. In addition, it helps to adequately relax the heart muscle during diastole.

The active substance Riboxin takes part in glucose metabolism and helps to restore ischemic tissue, and also stimulates the normalization of blood circulation in the coronary vessels. Treatment with this drug helps to reduce tissue hypoxia and activate all metabolic processes in the myocardium.

Indications for use

Lkx is assigned to him? The patient has to use the Riboxin prescribed by the doctor, with different dosages, for many reasons:

1. Prolonged excessive physical activity, negatively affecting the body as a whole;
2. Riboxin is in demand in sports, to support professional athletes during long training sessions;
3. There are indications for use in the diagnosis of uroporphyria (metabolic functions are disturbed);
4. Supplements the main composition of medicines for open-angle therapy;
5. Riboxin is indicated for oncology, for the duration of radiation therapy, which helps to facilitate the perception of the procedure and reduce the adverse response to its implementation;
6. In the complex treatment of coronary artery disease (ischemic disease). The start of taking a therapeutic drug is possible regardless of the phase of the disease, and during the recovery period after the incident;
7. Myocardium and cardiomyopathy initiate indications for long-term administration of Riboxin;
8. With the normalization of the heartbeat rhythm (). The best effect is achieved in the treatment of pathology provoked by an overdose of certain drugs;
9. Complex drug therapy for liver pathology: fatty degeneration, manifestation of toxic disorders in liver cells (a consequence of taking medications, complications in the performance of professional duties);
10. Riboxin is prescribed during pregnancy, at the discretion of the attending physician.

Contraindications

• hyperuricemia;
• gout;
• glucose / galactose malabsorption syndrome, fructose intolerance or isomaltase / sucrose deficiency (for film-coated tablets);
• age up to 18 years;
• the period of pregnancy and breastfeeding;
• hypersensitivity to the substances that make up the drug.

Caution in prescribing Riboxin should be observed in the presence of the following diseases / conditions:

• kidney failure;
• diabetes mellitus (for film-coated tablets).

Appointment during pregnancy and lactation

Riboxin during pregnancy is prescribed to many women. Many patients are frightened by the fact that in the instructions for the drug you can often find information that the drug is contraindicated for pregnant women. However, you should not be afraid of this, since the contraindication is based on the fact that clinical studies in this area have not yet been conducted. And this is despite the fact that today there is a lot of experience in the successful use of Riboxin during the gestation period. The medicine does not have a pathological effect on either the fetus or its mother, so there is no reason for concern. The only contraindication here can only be individual intolerance to the drug or its components.

Riboxin is an antihypoxant, an antioxidant, and a good means of improving metabolic processes in tissues, which is especially important during the period of bearing a child.

The drug is prescribed to prevent heart disease and support cardiac activity during periods of increased stress. Often, Riboxin is administered directly during childbirth, since the load on the heart at such a moment is especially great.

Doctors often prescribe a medicine if a pregnant woman has gastritis and liver diseases in order to treat existing problems. The drug helps to normalize the secretion of the stomach and reduce unpleasant symptoms.

Riboxin during pregnancy, the doctor may prescribe in case of detection of fetal hypoxia. By normalizing metabolic processes in tissues, the drug reduces the degree of oxygen starvation of the fetus.

With good tolerance, expectant mothers take the drug orally 1 tablet 3-4 times a day for 1 month. Despite the harmlessness of the drug, as in any other case, Riboxin should be prescribed by a doctor strictly on an individual basis.

Dosage and method of application

As indicated in the instructions for use, Riboxin is prescribed for adults inside, before meals.

1. The daily dose for oral administration is 0.6-2.4 g. In the first days of treatment, the daily dose is 0.6-0.8 g (200 mg 3-4 times a day). In case of good tolerance, the dose is increased (for 2-3 days) to 1.2 g (0.4 g 3 times a day), if necessary, up to 2.4 g per day.
2. The duration of the course is from 4 weeks to 1.5-3 months.

With urocoproporphyria, the daily dose is 0.8 g (200 mg 4 times a day). The drug is taken daily for 1-3 months.

injection solution

Methods of administration of Riboxin: intravenous bolus slowly or drip (40-60 drops in 1 minute).

The initial dose is 10 ml of a solution (200 mg of inosine) once a day, if the therapy is well tolerated by the patient, a single dose is increased by 2 times with a frequency of use 1-2 times a day. The duration of the drug is 10-15 days.

Jet administration of Riboxin is possible in case of acute cardiac arrhythmias, a single dose is from 10 to 20 ml.

For the purpose of pharmacological protection of the kidneys subjected to ischemia, the drug is administered intravenously by stream: for 5-15 minutes of turning off the blood circulation by clamping the kidney artery - 60 ml, and then another 40 ml immediately after the blood circulation is restored.

For drip administration, the Riboxin solution must be diluted to a volume of 250 ml (5% glucose (dextrose) solution or 0.9% sodium chloride solution).

Side effect

Side effects are possible, so after the first dose of the drug, you need to carefully monitor the patient's condition. Riboxin can cause the following undesirable reactions:

1. Headache, nausea, vomiting.
2. Exacerbation of gout, hyperuricemia.
3. General weakness.
4. Allergic reactions (including immediate type).
5. Rash, itching, skin changes.
6. Increased heart rate and drop in blood pressure.
7. Dizziness, increased sweating.
8. Discomfort at the injection site.

With the manifestation of side effects, the drug is canceled.

Overdose

Currently, cases of overdose with Riboxin tablets have not been established.

special instructions

During the period of treatment with Riboxin, the concentration of uric acid in the blood and urine should be monitored.

Information for patients with diabetes mellitus: 1 tablet of the drug corresponds to 0.00641 bread units.

Does not affect the ability to drive vehicles and control mechanisms that require increased concentration.

Interaction with other drugs

Pharmacological interactions are mainly manifested with drugs from other cardiac groups. Riboxin can enhance the effect of heparin, since it itself affects platelet aggregation.

It also enhances the inotropic effect of cardiac glycosides and prevents the occurrence of arrhythmias.

When taken simultaneously with drugs of the beta-blocker group, the effect of Riboxin does not change. It is also allowed to combine it with nitroglycerin, spironolactone, nifedipine, furosemide.

The solution is not compatible in the same container with pyridoxine, salts of heavy metals, alkaloids, acids. Riboxin cannot be mixed with other solvents other than those recommended.